Citations

Mayo Clinic

Showing 10 of 108585 citations.

AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis
Kaplan, David E. , Thiele, Maja , Fortune, Brett E. , García–Tsao, Guadalupe , Bosch, Jaime , Ripoll, Cristina , Thiele, Maja , Simonetto, Douglas A , Garcia-Tsao, Guadalupe , Bosch, Jaime , Simonetto, Douglas A.

Hepatology | October 23, 2023 | Volume: 79 | Issue: 5 | Pages: 1180-1211

10.1097/hep.0000000000000647 | PMID 37870298 Get It

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
Lewis, Gregory D. , Gosch, Kensey , Cohen, Laura , Nassif, Michael E. , Windsor, Sheryl L. , Borlaug, Barry A. , Kitzman, Dalane W. , Shah, Sanjiv J. , Khumri, Taiyeb, Umpierrez, Guillermo E. , Lamba, Sumant, Kosiborod, Mikhail , Umpierrez, Guillermo E. , Sharma, Kavita , Khan, Sadiya S , Kosiborod, Mikhail N , Borlaug, Barry A , Shah, Sanjiv J , Lewis, Gregory D , Windsor, Sheryl L , Sharma, Kavita , Khan, Sadiya S. , Sauer, Andrew J

Circulation: Heart Failure | October 23, 2023 | Volume: 16 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.123.010633 | PMID 37869881 Get It

BACKGROUND: Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive. We sought to explore the association between prespecified patient characteristics and changes in 6-minute walk distance that constitute a clinically significant response to dapagliflozin. METHODS: We performed a responder analysis to understand patient characteristics associated with clinically meaningful improvement in 6-minute walk test (6MWT) distance ≥15 m among patients randomized to 12 weeks of dapagliflozin versus placebo in the double-blind PRESERVED-HF trial (Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With Preserved Ejection Fraction Heart Failure). RESULTS: A total of 289 randomized patients had 6MWT distance completed at baseline and 12 weeks. Patients randomized to dapagliflozin improved walking distance by ≥15 m more frequently than those on placebo (n=64, 44% versus n=48, 34%). After adjusting for baseline covariates, patients randomized to dapagliflozin were more likely to experience a clinically meaningful improvement in 6MWT distance compared with those that received placebo (adjusted odds ratio, 1.66 [95% CI, 1.00–2.75]; P =0.05). Dapagliflozin-treated patients were also less likely to have a ≥15 m reduction in 6MWT distance compared with placebo-treated patients (adjusted odds ratio, 0.56 [95% CI, 0.33–0.94]; P =0.03). These results were consistent across all prespecified subgroups (all P values for interaction were not significant). CONCLUSIONS: Compared with those on placebo, patients with heart failure with preserved ejection fraction randomized to dapagliflozin were more likely to experience a clinically meaningful improvement and less likely to experience a deterioration in physical function over 12 weeks as measured by 6MWT distance. Beneficial response to dapagliflozin was consistent across prespecified subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03030235.
T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer disease
Brier, Matthew R. , Gordon, Brian A. , Flores, Shaney , Keefe, Sarah , Hornbeck, Russ C. , Ances, Beau M. , Xiong, Chengjie , Wang, Guoqiao , Raji, Cyrus A. , Libre‐Guerra, Jorge J., Perrin, Richard J. , Daniels, Alisha , Day, Gregory S. , Fulham, Michael , Jack, Clifford R. , Fougère, Christian la , Oh, Hwamee , Vöglein, Jonathan , Yakushev, Igor , Morris, John C. , (DIAN), For the Dominantly Inherited Alzheimer Network, Rahmani, Farzaneh , Cash, David M , Jack, Clifford R , Gordon, Brian A , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Ances, Beau M , Morris, John C , McKay, Nicole S. , Joseph‐Mathurin, Nelly , Xiong, Chengjie , McDade, Eric , Karch, Celeste M. , Brickman, Adam M. , Reischl, Gerald , Schofield, Peter R. , Cash, David M. , Ikeuchi, Takeshi , Klunk, William E. , Bateman, Randall J. , Benzinger, Tammie L.S. , (DIAN), For the Dominantly Inherited Alzheimer Network

Human Brain Mapping | October 23, 2023 | Volume: 44 | Issue: 18 | Pages: 6375-6387

10.1002/hbm.26514 | PMID 37867465 Get It

AbstractCarriers of mutations responsible for dominantly inherited Alzheimer disease provide a unique opportunity to study potential imaging biomarkers. Biomarkers based on routinely acquired clinical MR images, could supplement the extant invasive or logistically challenging) biomarker studies. We used 1104 longitudinal MR, 324 amyloid beta, and 87 tau positron emission tomography imaging sessions from 525 participants enrolled in the Dominantly Inherited Alzheimer Network Observational Study to extract novel imaging metrics representing the mean (μ) and standard deviation (σ) of standardized image intensities of T1‐weighted and Fluid attenuated inversion recovery (FLAIR) MR scans. There was an exponential decrease in FLAIR‐μ in mutation carriers and an increase in FLAIR and T1 signal heterogeneity (T1‐σ and FLAIR‐σ) as participants approached the symptom onset in both supramarginal, the right postcentral and right superior temporal gyri as well as both caudate nuclei, putamina, thalami, and amygdalae. After controlling for the effect of regional atrophy, FLAIR‐μ decreased and T1‐σ and FLAIR‐σ increased with increasing amyloid beta and tau deposition in numerous cortical regions. In symptomatic mutation carriers and independent of the effect of regional atrophy, tau pathology demonstrated a stronger relationship with image intensity metrics, compared with amyloid pathology. We propose novel MR imaging intensity‐based metrics using standard clinical T1 and FLAIR images which strongly associates with the progression of pathology in dominantly inherited Alzheimer disease. We suggest that tau pathology may be a key driver of the observed changes in this cohort of patients.
Establishment of a Labile Bound Copper Reference Interval in a Healthy Population via an Inductively Coupled Plasma Mass Spectrometry Dual Filtration–Based Assay
Bitzer, Anna C, Fox, Jessica, Day, Patrick L. , Wermers, Michelle, Jannetto, Paul J. , Bornhorst, Joshua A. , Bornhorst, Joshua , Fox, Jessica, Day, Patrick , Pazdernik, Vanessa , Smith, Carin Y.

Archives of Pathology & Laboratory Medicine | October 23, 2023 | Volume: 148 | Issue: 7 | Pages: 818-827

10.5858/arpa.2023-0259-oa | PMID 37870242 Get It

Context.— Clinical testing for Wilson disease (WD) is potentially challenging. Measuring the fraction of labile bound copper (LBC) to total copper may be a promising alternative diagnostic tool with better sensitivity and specificity than some current biomarker approaches. A dual filtration–based inductively coupled mass spectrometry (ICP-MS) assay to measure LBC in serum was developed. Objective.— To establish a reference interval for LBC and LBC to total copper (LBC fraction) in a healthy adult population, and to examine associations between total copper, LBC, and LBC fraction with age, sex, menopausal status, hormone replacement therapy, and supplement use. Design.— Serum samples were collected from healthy male (n = 110) and female (n = 104) patients between the ages of 19 and 80 years. Total copper and LBC were analyzed using ICP-MS. Results were used to calculate the LBC fraction. Reference intervals were calculated for the 2.5th and 97.5th percentiles for both LBC and LBC fraction. Results.— The reference intervals for LBC were determined to be 13 to 105 ng/mL and 12 to 107 ng/mL for female and male patients, respectively. The reference intervals for the LBC fraction were 1.0% to 8.1% and 1.2% to 10.5% for female and male patients, respectively. No significant associations were found regarding age, menopausal status, hormone replacement therapy, or vitamin and supplement use. Conclusions.— Sex-specific reference intervals have now been established for LBC and LBC fraction. These data in conjunction with further testing of WD populations can be used to assess the sensitivity and specificity of LBC fraction in screening, monitoring, and diagnosis.
Duration of Dialysis in Acute Kidney Injury Donors and Transplant Outcomes
Punukollu, Rachana , Ohara, Stephanie , Budhiraja, Pooja , Kumm, Kayla , Ruch, Brianna , Misra, Suman , Reddy, Kunam S. , Heilman, Raymond L. , Punukollu, Rachana , Budhiraja, Pooja , Smith, Maxwell L. , Jadlowiec, Caroline C.

Journal of the American College of Surgeons | October 23, 2023 | Volume: 238 | Issue: 1 | Pages: 61-69

10.1097/xcs.0000000000000870 | PMID 37870238 Get It

BACKGROUND: Acute kidney injury (AKI) kidneys, including those from donors on dialysis, are often underutilized, although there is increasing data available demonstrating good transplant outcomes. To date, data on the duration of donor dialysis and transplant outcomes are limited. STUDY DESIGN: This was a single-center study of deceased donor kidney transplants from 2010 to 2022. The study cohort consisted of recipients of deceased donor kidney transplants from donors with AKI and on dialysis. Three groups were identified based on the predetermined interquartile range of donor dialysis duration: 1 to 2 dialysis days, 3 to 4 dialysis days, and 5 or more dialysis days. RESULTS: During this period, 765 AKI deceased donor transplants were performed, of which 230 were from donors on dialysis. The median dialysis duration was 2 days with a maximum of 13 days. Across the 3 groups, there were no differences in recipient age (p = 0.23) or dialysis vintage (p = 0.70). Donor age (p = 0.86) and kidney donor profile index (p = 0.57) were comparable between the groups. Recipients of deceased donor kidney transplants from donors on dialysis 5 or more days had lower terminal creatinine levels (p = 0.003) and longer cold ischemia times (p = 0.04). Posttransplant, the median length of hospital stay was 3 days for all groups (p = 0.75). There were no differences in delayed graft function occurrence (94.4% vs 86.8% vs 92.1%, p = 0.19), duration of delayed graft function (p = 0.56), or readmissions (p = 0.99). At 1 year posttransplant, the estimated glomerular filtration rate (p = 0.76), patient survival (p = 0.82), or death-censored graft survival (p = 0.28) were comparable. CONCLUSIONS: Excellent outcomes have been observed in AKI deceased donor kidney transplants, including those coming from donors on dialysis. In this small cohort, the duration of donor dialysis did not adversely affect outcomes. Cautious expansion of the donor pool, including donors on dialysis, should be considered given the ongoing organ shortage.
Follicular thyroid carcinoma within a struma ovarii: a case report
Almnashef, Rasha, Menchaf, Ruba, Idres, Fatima A. , Aljammal, Ghina, Farho, Mohamad Ali , Ibrahim, Zain A , Abbassi, Haitham, Mansour, Marah , Farho, Mohamad Ali

Journal of Surgical Case Reports | October 22, 2023 | Volume: 2023 | Issue: 10 | Pages: No page available

10.1093/jscr/rjad584 | PMID 37873049 Get It

Abstract Struma ovarii comprises 1% of all ovarian tumors and 3% of ovarian teratomas. It occurs in older females. Struma ovarii is often asymptomatic, unilateral, and accidentally detected through abdominal ultrasound or computed tomography. It presents with palpable abdominal pain or irregular menstrual cycles. Generally, it is treated with surgical resection, even though the best procedure in these cases remains under discussion. In this study, we present a case of a 28-year-old female with severe pain in the right iliac fossa. Physical examination and radiological images showed a large mass. A bilateral salpingo-oophorectomy with omentectomy, a total mass resection, and an abdominal hysterectomy were performed. A biopsy confirmed the diagnosis of a follicular thyroid tumor. The management decision is based on clinical and pathological data. This is particularly challenging due to its rarity and the insufficient guidelines regarding the management of this type of cancer.
Investigating the Pathogenic Interplay of Alpha-Synuclein, Tau, and Amyloid Beta in Lewy Body Dementia: Insights from Viral-Mediated Overexpression in Transgenic Mouse Models
Lim, Melina J., Boschen, Suelen L. , Kurti, Aishe, Casey, Monica Castanedes, Phillips, Virginia , Fryer, John Denis , Jansen‐West, Karen , Petrucelli, Leonard , Delenclos, Marion , McLean, Pamela J. , Castanedes Casey, Monica, Phillips, Virginia R, Boschen, Suelen L , McLean, Pamela J , Dickson, Dennis W.

Biomedicines | October 22, 2023 | Volume: 11 | Issue: 10 | Pages: 2863

10.3390/biomedicines11102863 | PMID 37893236 Get It

Lewy body dementia (LBD) is an often misdiagnosed and mistreated neurodegenerative disorder clinically characterized by the emergence of neuropsychiatric symptoms followed by motor impairment. LBD falls within an undefined range between Alzheimer’s disease (AD) and Parkinson’s disease (PD) due to the potential pathogenic synergistic effects of tau, beta-amyloid (Aβ), and alpha-synuclein (αsyn). A lack of reliable and relevant animal models hinders the elucidation of the molecular characteristics and phenotypic consequences of these interactions. Here, the goal was to evaluate whether the viral-mediated overexpression of αsyn in adult hTau and APP/PS1 mice or the overexpression of tau in Line 61 hThy1-αsyn mice resulted in pathology and behavior resembling LBD. The transgenes were injected intravenously via the tail vein using AAV-PHP.eB in 3-month-old hThy1-αsyn, hTau, or APP/PS1 mice that were then aged to 6-, 9-, and 12-months-old for subsequent phenotypic and histological characterization. Although we achieved the widespread expression of αsyn in hTau and tau in hThy1-αsyn mice, no αsyn pathology in hTau mice and only mild tau pathology in hThy1-αsyn mice was observed. Additionally, cognitive, motor, and limbic behavior phenotypes were not affected by overexpression of the transgenes. Furthermore, our APP/PS1 mice experienced premature deaths starting at 3 months post-injection (MPI), therefore precluding further analyses at later time points. An evaluation of the remaining 3-MPI indicated no αsyn pathology or cognitive and motor behavioral changes. Taken together, we conclude that the overexpression of αsyn in hTau and APP/PS1 mice and tau in hThy1-αsyn mice does not recapitulate the behavioral and neuropathological phenotypes observed in LBD.
Incidence and Outcomes of Bloodstream Infection After Arterial Aneurysm Repair: Findings From a Population-Based Study
Tabaja, Hussam , Chesdachai, Supavit , Lahr, Brian D. , Chesdachai, Supavit , Tabaja, Hussam , Baddour, Larry M. , DeMartino, Randall R. , DeSimone, Daniel C.

Open Forum Infectious Diseases | October 21, 2023 | Volume: 10 | Issue: 11 | Pages: No page available

10.1093/ofid/ofad521 | PMID 38023557 Get It

Abstract Background Limited research has focused on bloodstream infection (BSI) in patients with arterial grafts. This study aims to describe the incidence and outcomes of BSI after arterial aneurysm repair in a population-based cohort. Methods The expanded Rochester Epidemiology Project (e-REP) was used to analyze aneurysm repairs in adults (aged ≥18 years) residing in 8 counties in southern Minnesota from January 2010 to December 2020. Electronic records were reviewed for the first episode of BSI following aneurysm repair. BSI patients were assessed for vascular graft infection (VGI) and followed for all-cause mortality. Results During the study, 643 patients had 706 aneurysm repairs: 416 endovascular repairs (EVARs) and 290 open surgical repairs (OSRs). Forty-two patients developed BSI during follow-up. The 5-year cumulative incidence of BSI was 4.7% (95% confidence interval [CI], 3.0%–6.4%), with rates of 4.0% (95% CI, 1.8%–6.2%) in the EVAR group and 5.8% (95% CI, 2.9%–8.6%) in the OSR group (P = .052). Thirty-nine (92.9%) BSI cases were monomicrobial, 33 of which were evaluated for VGI. VGI was diagnosed in 30.3% (10/33), accounting for 50.0% (8/16) of gram-positive BSI cases compared to 11.8% (2/17) of gram-negative BSI cases (P = .017). The 1-, 3-, and 5-year cumulative post-BSI all-cause mortality rates were 22.2% (95% CI, 8.3%–34.0%), 55.8% (95% CI, 32.1%–71.2%), and 76.8% (95% CI, 44.3%–90.3%), respectively. Conclusions The incidence of BSI following aneurysm repair was overall low. VGI was more common with gram-positive compared to gram-negative BSI. All-cause mortality following BSI was high, which may be attributed to advanced age and significant comorbidities in our cohort.
Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial
Al‐Khazali, Haidar M. , Christensen, Rune Häckert , Chaudhry, Basit Ali , Burstein, Rami , Ashina, Håkan , Christensen, Rune H. , Ashina, Sait , Burstein, Rami , Ashina, Håkan , Ashina, Sait , Al-Khazali, Haidar M , Dodick, David W. , Amin, Faisal Mohammad

Brain | October 21, 2023 | Volume: 147 | Issue: 4 | Pages: 1312-1320

10.1093/brain/awad367 | PMID 37864847 Get It

Abstract Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), known for its role in migraine pathogenesis, has been identified as a novel drug target. Given the clinical parallels between post-traumatic headache (PTH) and migraine, we explored the possible role of PACAP-38 in the pathogenesis of PTH. To this end, we conducted a randomized, double-blind, placebo-controlled, two-way crossover trial involving adult participants diagnosed with persistent PTH resulting from mild traumatic brain injury. Participants were randomly assigned to receive a 20-min continuous intravenous infusion of either PACAP-38 (10 pmol/kg/min) or placebo (isotonic saline) on two separate experimental days, with a 1-week washout period in between. The primary outcome was the difference in incidence of migraine-like headache between PACAP-38 and placebo during a 12-h observational period post-infusion. The secondary outcome was the difference in the area under the curve (AUC) for baseline-corrected median headache intensity scores during the same 12-h observational period. Of 49 individuals assessed for eligibility, 21 were enrolled and completed the trial. The participants had a mean age of 35.2 years, and 16 (76%) were female. Most [19 of 21 (90%)] had a migraine-like phenotype. During the 12-h observational period, 20 of 21 (95%) participants developed migraine-like headache after intravenous infusion of PACAP-38, compared with two (10%) participants after placebo (P < 0.001). Furthermore, the baseline-corrected AUC values for median headache intensity scores during the 12-h observational period was higher after PACAP-38 than placebo (P < 0.001). These compelling results demonstrate that PACAP-38 is potent inducer of migraine-like headache in people with persistent PTH. Thus, targeting PACAP-38 signalling might be a promising avenue for the treatment of PTH.